Silence Therapeutics Plc has appointed Tim Freeborn, a chartered accountant, as its new finance director. Mr Freeborn joins Silence, which focuses on RNA interference (RNAi) technology, from Xcap Securities Plc where he was head of research.
Silence Therapeutics announced the appointment on 15 October 2012.
Copyright 2012 Evernow Publishing Ltd